Alliancebernstein L.P. Akebia Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $290 Billion
- Q2 2025
A detailed history of Alliancebernstein L.P. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 238,930 shares of AKBA stock, worth $528,035. This represents 0.0% of its overall portfolio holdings.
Number of Shares
238,930
Previous 52,270
357.11%
Holding current value
$528,035
Previous $100,000
769.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AKBA
# of Institutions
174Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$32.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$25.7 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$17.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$13.4 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.7 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $406M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...